Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.
Vici P, Crispo A, Giordano A, Di Lauro L, Sperati F, Terrenato I, Pizzuti L, Sergi D, Mottolese M, Botti C, Grimaldi M, Capasso I, D'Aiuto G, Di Bonito M, Di Paola F, Maugeri-Saccà M, Montella M, Barba M. Vici P, et al. Among authors: mottolese m. J Cell Physiol. 2015 Aug;230(8):1708-12. doi: 10.1002/jcp.24891. J Cell Physiol. 2015. PMID: 25510909
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, Barba M. Vici P, et al. Among authors: mottolese m. Oncotarget. 2014 Nov 15;5(21):10382-92. doi: 10.18632/oncotarget.2060. Oncotarget. 2014. PMID: 25071015 Free PMC article.
Triple positive breast cancer: a distinct subtype?
Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, Sergi D, Botti C, Michelotti A, Moscetti L, Mariani L, Izzo F, D'Onofrio L, Sperduti I, Conti F, Rossi V, Cassano A, Maugeri-Saccà M, Mottolese M, Marchetti P. Vici P, et al. Among authors: mottolese m. Cancer Treat Rev. 2015 Feb;41(2):69-76. doi: 10.1016/j.ctrv.2014.12.005. Epub 2014 Dec 19. Cancer Treat Rev. 2015. PMID: 25554445 Free article. Review.
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anzà M, Maugeri-Saccà M, Natoli C, Di Filippo S, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Di Lauro L, Sanguineti G, Di Benedetto A, Giordano A, Vici P. Pizzuti L, et al. Among authors: mottolese m. J Cell Physiol. 2016 Nov;231(11):2541-7. doi: 10.1002/jcp.25432. Epub 2016 Jun 2. J Cell Physiol. 2016. PMID: 27187274 Free PMC article. Clinical Trial.
Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer.
Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Humphries MP, Sundara-Rajan S, Barba M, Speirs V, De Maria R, Maugeri-Saccà M. Di Benedetto A, et al. Among authors: mottolese m. J Cell Physiol. 2017 Aug;232(8):2246-2252. doi: 10.1002/jcp.25745. Epub 2017 Mar 3. J Cell Physiol. 2017. PMID: 27987320 Free article.
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
Barba M, Vici P, Pizzuti L, Di Lauro L, Sergi D, Di Benedetto A, Ercolani C, Sperati F, Terrenato I, Botti C, Mentuccia L, Iezzi L, Gamucci T, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M. Barba M, et al. Among authors: mottolese m. BMC Cancer. 2017 Feb 6;17(1):101. doi: 10.1186/s12885-016-3045-z. BMC Cancer. 2017. PMID: 28166748 Free PMC article.
Androgen receptor and antiandrogen therapy in male breast cancer.
Di Lauro L, Barba M, Pizzuti L, Vici P, Sergi D, Di Benedetto A, Mottolese M, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. Di Lauro L, et al. Among authors: mottolese m. Cancer Lett. 2015 Nov 1;368(1):20-25. doi: 10.1016/j.canlet.2015.07.040. Epub 2015 Aug 11. Cancer Lett. 2015. PMID: 26276719 Free article. Review.
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: mottolese m. Oncotarget. 2014 Oct 30;5(20):9619-25. doi: 10.18632/oncotarget.2449. Oncotarget. 2014. PMID: 25294813 Free PMC article. Clinical Trial.
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
Botti C, Buglioni S, Benevolo M, Giannarelli D, Papaldo P, Cognetti F, Vici P, Di Filippo F, Del Nonno F, Venanzi FM, Natali PG, Mottolese M. Botti C, et al. Among authors: mottolese m. Clin Cancer Res. 2004 Feb 15;10(4):1360-5. doi: 10.1158/1078-0432.ccr-1092-03. Clin Cancer Res. 2004. PMID: 14977837
243 results